Gufic Biosciences

What Gufic Biosciences does

Gufic Biosciences Limited is a publicly listed Indian pharmaceutical company founded in 1970 and headquartered in Mumbai, with 2,500+ employees and operations across 50+ countries. The company specializes in complex sterile injectables, lyophilized formulations, and active pharmaceutical ingredients (APIs), organized into seven therapeutic divisions: Criticare (critical care, 5,000+ hospitals, 130+ registered products), Ferticare and FertiMax (fertility/IVF, ranked among India's top 5), Aesthaderm (medical aesthetics, including India's first indigenous Botulinum Toxin Type A, Stunnox), Sparsh (cardiac and emergency care), Zenova (gynecology, IVF, orthopedics), NeuroCare (neurology, including indigenous Zarbot botulinum toxin), and Healthcare (standardized Ayurvedic and nutraceutical products such as Sallaki). Underlying capabilities include pioneering automated lyophilization with zero-human-touch manufacturing, dual-chamber bag and syringe technology (sourced from Technoflex France), complex API manufacturing (with ~50% market share in India's Prilocaine exports), and a 20-year patent on Omadacycline Tosylate.

The company manufactures at three Indian sites: Navsari (Gujarat) with 3.0M vials/month and 1,200+ workforce, Pithampur/Indore (Madhya Pradesh) with USD 50M invested, 14,559 m² built-up area, and capacity for 60M lyophilized and 72M liquid injections annually, plus Belgaum (Karnataka). Internationally, Gufic Ireland Limited provides direct EU presence with 10+ product filings across 18 EU markets including the UK, supported by 45+ global regulatory approvals (EU GMP, MHRA, Health Canada, TGA, ANVISA, SAHPRA, Russian GMP, NMPA). Revenue mechanics are based on one-time sales of pharmaceutical formulations and APIs to hospital chains, medical institutions, IVF specialists, aesthetic practitioners, and government health systems; exports account for 75% of API revenue, and the bulk drug business contributes 10% of group turnover. Q3 FY2026 (Dec 2025) consolidated sales reached Rs 231.41 crore (+11.37% YoY), with net profit declining 35.68% YoY to Rs 12.42 crore.

Name

Gufic Biosciences

Legal name

Gufic Biosciences Limited

Website

https://gufic.com

Company type

Public

Founded year

1970

Operating status

Operating

Headcount range

11–50 employees

Short description

Gufic Biosciences is a publicly listed Indian pharmaceutical company (founded 1970, 2,500+ employees) specializing in complex sterile injectables, lyophilized formulations, and APIs across seven therapeutic divisions, exporting to 50+ countries with manufacturing in India and a direct EU presence via Gufic Ireland.

Ownership category

akta.pro rank

Product category

Sterile Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Sterile Injectable Generics (HLAIABAC)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB), Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

Keywords

• Sterile injectable pharmaceuticals
• Lyophilized formulations manufacturing
• Active pharmaceutical ingredients
• Critical care injectables
• Fertility pharmaceuticals

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Formulations (Injectables): Sale of sterile injectable formulations including lyophilized vials, liquid injectables, ampoules, dry powder vials, pre-filled syringes, cartridge dosage, and dual chamber bags. These are sold domestically to hospital chains and medical institutions, and exported to 50+ countries across regulated and emerging markets.
2. Active Pharmaceutical Ingredients (APIs): Manufacture and sale of bulk drug APIs (Prilocaine, Avibactam Sodium, Lidocaine, Miconazole, Isoconazole Nitrate, Econazole) for both domestic distribution and global export markets. API business contributes 10% to group turnover with 75% revenue from exports.
3. Ayurvedic and Natural Healthcare Products: Sale of Ayurvedic and nutraceutical products (Sallaki, Gufispon, Nucart-VG, Gufican Oil) through the Healthcare division, integrating classical Ayurvedic wisdom with modern pharmaceutical standards.
4. Medical Aesthetics Products: Sale of medical aesthetics products including Stunnox (indigenous botulinum toxin for anti-wrinkle treatment), in-licensed fillers and biostimulators through the Aesthaderm division.
5. Fertility and IVF Products: Sale of fertility pharmaceuticals including gonadotropins (Puregraf, Supergraf, Unogem), and advanced injectables through the Ferticare and FertiMax divisions, serving IVF specialists across India.
6. Neurological Therapeutics (Botulinum Toxin): Sale of Zarbot, India's first indigenously manufactured Botulinum Toxin Type A injection for neurological disorders, produced in partnership with Prime Bio, USA.
7. Fertility Diagnostics and Devices: Fertility science products and solutions through FertiMax superspeciality division, including Guficin Alpha and advanced gonadotropin formulations.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Gufic Biosciences manufactures and markets sterile injectable pharmaceutical formulations including lyophilized vials, liquid injectables, ampoules, dry powder vials, pre-filled syringes, and dual chamber bags. The company also produces active pharmaceutical ingredients (APIs) such as Prilocaine, Lidocaine, Miconazole, and Avibactam Sodium for domestic and global markets. Products span critical care anti-infectives, fertility pharmaceuticals, botulinum toxin for aesthetics and neurology, and Ayurvedic healthcare, supplied to 5,000+ hospitals in India and exported to 50+ countries.

Product overview

Gufic Biosciences Limited is a diversified pharmaceutical company offering a comprehensive portfolio of products organized across multiple divisions and business verticals. The company operates as a platform with distinct therapeutic divisions including Critical Care (Criticare), Ferticare, Aestharderm, Sparsh, Healthcare, Zenova, and NeuroCare. Core offerings include: injectables (lyophilized vials, liquid injectables, ampoules, dry powder vials, pre-filled syringes, cartridge dosage, dual chamber bags, LVP liquid vials); APIs (Prilocaine, Avibactam Sodium, Lidocaine, Miconazole, Isoconazole Nitrate, Econazole); critical care products (Vancomycin, Teicoplanin, Caspofungin, Liposomal Amphotericin B); fertility solutions (Puregraf, Cetrocare, FertiMax); medical aesthetics (Stunnox botulinum toxin); neurological therapeutics (Zarbot botulinum toxin); and Ayurvedic/natural healthcare products (Sallaki, Gufispon, Nucart-VG). Manufacturing infrastructure includes FDA-approved facilities in Navsari (Gujarat), Pithampur (Madhya Pradesh), and Belgaum (Karnataka), with international presence through Gufic Ireland Limited. The company exports to 50+ countries with 2500+ team members and 300+ brands.

Differentiator

Problem solved

Functional benefit

Brands

• Criticare: Critical care division delivering lyophilized formulations trusted by 5,000+ hospitals pan India with 130+ globally registered products across 15+ countries.
• Ferticare
• Aestharderm
• Sparsh
• Healthcare
• Zenova
• Neurocare
• FertiMax
• Gufic Ireland Limited

Products and services

• Sterile Injectable Formulations Sterile injectable pharmaceutical formulations including lyophilized vials, liquid injectables, ampoules, dry powder vials, pre-filled syringes, cartridge dosage, and dual chamber bags sold domestically to hospital chains and exported to 50+ countries across regulated and emerging markets.
• Bulk Drug APIs (Active Pharmaceutical Ingredients) Manufacture and sale of bulk drug APIs including Prilocaine (with ~50% market share in India's exports), Avibactam Sodium, Lidocaine, Miconazole, Isoconazole Nitrate, and Econazole for domestic distribution and global export markets. API business contributes 10% to group turnover with 75% revenue from exports.
• Criticare Critical Care Pharmaceuticals Critical care division offering 130+ globally registered products including anti-infectives, antifungals, immunomodulators, and complex injectables for ICU and emergency medicine. Trusted by 5,000+ hospitals pan India and 25,000+ healthcare professionals. Key brands include Immunocin Alpha (Thymosin Alpha-1), Dalbavan (Dalbavancin), Guficap (Caspofungin), Micafung Plus, Doxific, Canidula, and Isavufic (Isavuconazole).
• Ferticare Fertility Pharmaceuticals Fertility division ranked among India's top five fertility pharmaceutical companies offering science-backed fertility solutions including gonadotropins and advanced injectables. Brands include Puregraf, Cetrocare, Luprocare Depot, Lomocare Pen, and Puretrig.
• FertiMax Superspeciality Fertility Division Superspeciality fertility division introducing India's first super-pure gonadotropins developed with Fractochrome technology (Supergraf and Unogem) and advancing reproductive immunology into clinical practice through products like Guficin Alpha.
• Stunnox (Botulinum Toxin for Aesthetics) India's first indigenously developed botulinum toxin Type A for anti-wrinkle treatment under the Aesthaderm division. Trusted by 1,000+ aesthetic practitioners with 70,000+ satisfied patients.
• Zarbot (Botulinum Toxin for Neurology) India's first domestically manufactured botulinum toxin Type A injection for treatment of various therapeutic neurological conditions under the NeuroCare division.
• Sparsh Division Pharmaceuticals Division delivering lifesaving medicines across critical care, cardiac emergencies, and contrast media for diagnostic imaging, addressing unmet medical needs in ICU settings.
• Healthcare Ayurvedic and Nutraceutical Products Ayurvedic and nutraceutical products integrating classical Ayurvedic wisdom with modern pharmaceutical standards. Brands include Sallaki (standardized Boswellic acids), Sallaki Liniment, Sallaki-MR, Gufispon, Nucart-VG (India's first vegetarian glucosamine), and Gufican Oil.
• Zenova Division Pharmaceuticals Focused healthcare division spanning Gynecology, IVF, and Orthopedics with 209 professionals across 8 key geographies (Maharashtra, UP, MP, Chhattisgarh, Rajasthan, AP, Telangana, West Bengal).
• International Export Product Portfolio Critical care injectable pharmaceuticals exported to 50+ countries including Vancomycin (500/1000 mg, registered across 16 EU countries), Teicoplanin (200/400 mg), Pantoprazole (40 mg, EU approvals for UK and Hungary), Clarithromycin (500 mg, UK approval), Colistimethate (1 and 2 MIU, UK and Germany approvals), Azithromycin (500 mg), Tigecycline (50 mg), Caspofungin (50 and 70 mg, Germany approvals), Omeprazole (40 mg, UK and Hungary approvals), and Liposomal Amphotericin B.

Quantifiable outcome

• India's first indigenously manufactured Botulinum Toxin Type A (Stunnox for aesthetics, Zarbot for neurology)
• +6 more outcomes

Named customers5 records

Segments9 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Four partnerships are on record, tiered core.

• Selvax (Australia)coreStrategic or Co-development Partner · 9 March 2022Oncology immunotherapy collaboration. Gufic entered into a research collaboration with Selvax Pty Ltd, Australia for Selvax Immunotherapy targeting pancreatic cancer. In April 2026, Gufic invested $50,000 in Selvax to develop immunotherapy solutions for oncology. Research collaboration undertaking announced March 9, 2022.
• Spectropharma (Saudi Arabia)coreChannel Partner/ Reseller/ DistributorMarket entry and distribution partnership for GCC region. Spectropharma serves as Gufic's channel partner for market access and distribution of sterile injectable products in Saudi Arabia and broader Gulf Cooperation Council markets.
• Prime Bio, USAcoreStrategic or Co-development PartnerStrategic partnership for indigenous Botulinum Toxin Type A manufacturing. Prime Bio, USA provides technology and expertise for Gufic's domestic manufacturing of botulinum toxin at Navsari, Gujarat, making Gufic one of a select few companies globally capable of this specialized production. Products include Stunnox (aesthetics) and Zarbot (neurology).
• Technoflex (France)coreTechnology or IntegrationTechnology partnership for dual-chamber bag technology. Technoflex, France provides dual-chamber bag technology enabling Gufic to produce safer closed delivery systems for unstable drugs with zero human intervention, addressing critical needs in IV therapy and improving drug stability.

Scale indicators24 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Biological E: Indian vaccines and biologicals manufacturer with injectable capabilities and a broad emerging-market footprint. Comparable on sterile injectable manufacturing, biologicals, and India-anchored manufacturing with international expansion.
• Venus Remedies: Indian critical-care injectable player with anti-infectives, antifungals, and oncology injectables sold across regulated and emerging markets. Closely comparable on therapeutic focus (critical care injectables) and export-led growth model.
• Bharat Serums and Vaccines: India-based specialty injectable and biological company (now part of Mankind Pharma) with a focused portfolio in critical care, fertility hormones, and women's health. Directly comparable to Gufic on therapeutic segmentation, lyophilized injectables, and India-plus-emerging-market distribution model.
• Gland Pharma: Indian sterile injectables specialist with deep US-FDA exposure supplying complex injectables and lyophilized products globally. Closest comparable on injectable manufacturing platform, regulatory breadth, and reliance on international regulated markets.
• Strides Pharma: Bangalore-based specialty pharma with significant sterile injectables franchise across regulated and emerging markets. Comparable on injectable manufacturing, complex generic filings, and emerging-market tender exposure.

Broad incumbents

• Aurobindo Pharma: Large Indian generic pharma with substantial sterile injectables, API manufacturing, and US-FDA-approved facilities. Overlaps with Gufic on sterile injectables and APIs but operates at materially larger scale and broader portfolio.
• Dr. Reddy's Laboratories: Indian pharma major with API manufacturing, sterile injectables, biosimilars, and strong regulated-market presence. Comparable on API-to-formulation integration and emerging/regulated-market split.
• Cipla: Major Indian pharma with complex generics, injectables, and global regulated-market presence. Overlaps with Gufic on critical care, anti-infectives, and emerging-market distribution, but is far larger and broader.
• Sun Pharmaceutical Industries: India's largest pharma company with sterile injectables, specialty portfolio, and global manufacturing. Overlaps with Gufic on sterile injectables and international expansion but at significantly greater scale and product breadth.

Regional players

• Alkem Laboratories: Indian pharma with strong anti-infective, critical care, and injectable portfolio primarily serving India and select international markets. Comparable therapeutic focus in critical care injectables and Indian-market dominance.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gufic-health-care-limited

Compliance41 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gufic Biosciences